United Therapeutics Rises: Analyst Upgrades Push Target to $600‑Plus Amid Growth Outlook
United Therapeutics’ analyst upgrades to mid‑$600s reflect strong QALY‑based pricing, digital‑manufacturing gains and patient‑access wins that drive 8‑10 % growth.
4 minutes to read
